# Zura Bio Ltd (ZURA)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/zura-bio-ltd/ JSON: https://steadybase.io/company/zura-bio-ltd.json Checked Nov 21, 2026. Latest filing read: Oct 27, 2026.

## Company

- Legal name: Zura Bio Ltd
- Ticker: ZURA (Nasdaq)
- SEC CIK: 0001855644
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: La Jolla, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: zurabio.com
- LinkedIn: https://www.linkedin.com/company/zura-bio-limited
- Next earnings date: Feb 11, 2027

## Key facts

- Operating income: -$75.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/0001104659-26-032080-index.html
- Net income: -$68.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/0001104659-26-032080-index.html
- SG&A: $33.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/0001104659-26-032080-index.html
- Employees: 40 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm
- Shares outstanding: 96,325,411 as of Oct 27, 2026 (10-Q filed Oct 27, 2026). Source: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000011/0001855644-26-000011-index.html
- Auditor: Withumsmith+Brown, Pc, East Brunswick, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm

## Business

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm

## Officers and directors

- Sandeep Chidambar Kulkarni, Chief Executive Officer. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000194569126000005/0001945691-26-000005-index.htm
- Eric J. Hyllengren, Chief Financial Officer. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000196692626000002/0001966926-26-000002-index.htm
- Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary. Source: 8-K filed May 22, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926065730/tm2615441d1_8k.htm
- Gary Whale, Chief Technology Officer. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000196586026000002/0001965860-26-000002-index.htm
- Marlyn Teresa Mathew, VP, Principal Acctg. Officer. Source: Form 3 filed Jun 22, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000213766326000003/0002137663-26-000003-index.htm
- Asim Mohammed, BAFFX17 Parties. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm
- Baljit Lehal, Stone Peach Parties. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm
- Kanwarjeet “Shawn” Tucker, Stone Peach Parties. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm
- Lahmber Singh, BAFFX17 Parties. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm
- Amit D. Munshi, Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926052942/tm261622-1_def14a.htm
- Dan Becker, M.D., Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926052942/tm261622-1_def14a.htm
- Kiran Nistala, Named in proxy. Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926052942/tm261622-1_def14a.htm
- Mark Eisner, M.D., M.P.H., Board member (per proxy). Source: DEF 14A filed Apr 30, 2026, https://www.sec.gov/Archives/edgar/data/1855644/000110465926052942/tm261622-1_def14a.htm

## Recent 8-K events

- Nov 9, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926124149/tm2629310d1_8k.htm
- Oct 27, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000012/zura-20261027.htm
- Aug 17, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926097526/tm2623351d1_8k.htm
- Aug 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811.htm
- Jul 1, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926079538/tm2619483d1_8k.htm
- Jun 18, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926075826/tm2618327d1_8k.htm
- May 22, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926065730/tm2615441d1_8k.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000162828026031701/zura-20260507.htm
- Apr 23, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926047784/tm2612540d1_8k.htm
- Mar 19, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/tm269296d1_8k.htm

## Latest filings

- 8-K filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000012/zura-20261027.htm
- 10-K filed Mar 19, 2026: https://www.sec.gov/Archives/edgar/data/1855644/000110465926032080/zura-20251231x10k.htm
- 10-Q filed Oct 27, 2026: https://www.sec.gov/Archives/edgar/data/1855644/000185564426000011/zura-20260930.htm
- DEF 14A filed Apr 30, 2026: https://www.sec.gov/Archives/edgar/data/1855644/000110465926052942/tm261622-1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

